|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-8-14
|
|
pubmed:abstractText |
We conducted a multicenter prospective study to evaluate the efficacy and safety of reduced-dose three-course CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) followed by involved-field radiotherapy for elderly patients with localized aggressive non-Hodgkin's lymphoma. The primary endpoint was compliance with the combined modality.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0360-3016
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
66
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
217-22
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16814951-Aged,
pubmed-meshheading:16814951-Aged, 80 and over,
pubmed-meshheading:16814951-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16814951-Combined Modality Therapy,
pubmed-meshheading:16814951-Cyclophosphamide,
pubmed-meshheading:16814951-Doxorubicin,
pubmed-meshheading:16814951-Drug Administration Schedule,
pubmed-meshheading:16814951-Female,
pubmed-meshheading:16814951-Humans,
pubmed-meshheading:16814951-Lymphoma, Non-Hodgkin,
pubmed-meshheading:16814951-Male,
pubmed-meshheading:16814951-Prednisolone,
pubmed-meshheading:16814951-Prospective Studies,
pubmed-meshheading:16814951-Radiotherapy Dosage,
pubmed-meshheading:16814951-Survival Rate,
pubmed-meshheading:16814951-Vincristine
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
A prospective study of reduced-dose three-course CHOP followed by involved-field radiotherapy for patients 70 years old or more with localized aggressive non-Hodgkin's lymphoma.
|
|
pubmed:affiliation |
Department of Radiology, Shinshu University School of Medicine, Matsumoto, Japan. shikama@hsp.md.shinshu-u.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
